United States - English - NLM (National Library of Medicine)

la jolla pharmaceutical company - angiotensin ii (unii: m089efu921) (angiotensin ii - unii:m089efu921) - angiotensin ii 2.5 mg in 1 ml - giapreza increases blood pressure in adults with septic or other distributive shock [see clinical studies (14)] . none. risk summary the published data on angiotensin ii use in pregnant women are not sufficient to determine a drug-associated risk of adverse developmental outcomes. animal reproduction studies have not been conducted with giapreza. all pregnancies have a background risk of birth defects, loss, or other adverse outcomes. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. clinical considerations disease-associated maternal and/or embryo/fetal risk septic or other distributive shock is a medical emergency that can be fatal if left untreated. delaying treatment in pregnant women with hypotension associated with septic or other distributive shock is likely to incr

European Union - English - EMA (European Medicines Agency)

paion deutschland gmbh - angiotensin ii acetate - hypotension; shock - agents acting on the renin-angiotensin system - giapreza is indicated for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies.

European Union - English - EMA (European Medicines Agency)

novartis europharm ltd. - amlodipine, valsartan, hydrochlorothiazide - hypertension - angiotensin ii antagonists, plain, angiotensin ii antagonists, combinations - treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (hct), taken either as three single-component formulations or as a dual-component and a single-component formulation.

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - telmisartan - hypertension - angiotensin ii antagonists, plain - hypertensiontreatment of essential hypertension in adults.cardiovascular preventionreduction of cardiovascular morbidity in patients with:manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or;type-2 diabetes mellitus with documented target-organ damage.

European Union - English - EMA (European Medicines Agency)

krka, d.d., novo mesto  - telmisartan - hypertension - angiotensin ii antagonists, plain - hypertensiontreatment of essential hypertension in adults.cardiovascular preventionreduction of cardiovascular morbidity in patients with:manifest atherothrombotic cardiovascular disease (history of coronary heart disease or peripheral arterial disease) or;type 2 diabetes mellitus with documented target organ damage.

European Union - English - EMA (European Medicines Agency)

novartis europharm limited - amlodipine, valsartan, hydrochlorothiazide - hypertension - angiotensin ii antagonists, combinations, agents acting on the renin-angiotensin system, angiotensin ii antagonists and calcium channel blockers - treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (hct), taken either as three single-component formulations or as a dual-component and a single-component formulation.

European Union - English - EMA (European Medicines Agency)

teva b.v. - telmisartan - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension in adults.

European Union - English - EMA (European Medicines Agency)

teva b.v. - telmisartan - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension in adults

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - losartan potassium - oral tablet - 100mg

European Union - English - EMA (European Medicines Agency)

krka, d.d., novo mesto - irbesartan hydrochloride - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension.treatment of renal disease in patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen.